NCT00269906View on ClinicalTrials.gov

A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty

PHASE3CompletedINTERVENTIONAL
Enrollment

1,265

Participants

Timeline

Start Date

May 31, 1993

Primary Completion Date

December 31, 1995

Study Completion Date

December 31, 1995

Conditions
Angina, UnstableAngioplasty, Transluminal, Percutaneous Coronary
Interventions
DRUG

Abciximab

DRUG

Placebo

Sponsors

Lead Sponsor

Centocor, Inc.
All Listed Sponsors
lead

Centocor, Inc.

INDUSTRY

NCT00269906 - A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty | Biotech Hunter | Biotech Hunter